grant

Sex-dependent APOE4 regulation of neutrophil-microglia crosstalk in Alzheimer's disease

Organization BRIGHAM AND WOMEN'S HOSPITALLocation BOSTON, UNITED STATESPosted 1 Feb 2022Deadline 30 Nov 2026
NIHUS FederalResearch GrantFY2026AD brainAD dementiaAD patientsAD riskAD risk factorAD therapyAD treatmentAPOEAPOE e4APOE-ε4APOEε4APP-PS1APP/PS1AccelerationAcuteAffectAllelesAllelomorphsAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer disease treatmentAlzheimer risk factorAlzheimer sclerosisAlzheimer syndromeAlzheimer treatmentAlzheimer'sAlzheimer's DiseaseAlzheimer's brainAlzheimer's disease brainAlzheimer's disease patientAlzheimer's disease riskAlzheimer's disease therapyAlzheimer's patientAlzheimer's therapyAlzheimers DementiaAmentiaAmyloid (Aβ) plaquesAmyloid PlaquesApo-EApoE proteinApolipoprotein EAreaAstrocytesAstrocytusAstrogliaBasic ResearchBasic ScienceBloodBlood NeutrophilBlood Polymorphonuclear NeutrophilBlood Reticuloendothelial SystemBrainBrain DiseasesBrain DisordersBrain Nervous SystemCell BodyCell Communication and SignalingCell SignalingCellsChronicClinicCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalDataDegenerative Neurologic DisordersDementiaDiseaseDisease ProgressionDisease associated microgliaDisorderDisturbance in cognitionEncephalonEncephalon DiseasesFemaleGenderGeneticGenetic predisposing factorGenotypeGliosisGoalsHortega cellHumanImmune responseImmunityImmunomodulationImpaired cognitionIn VitroInfiltrationInflammatoryInflammatory ResponseInnate ImmunityIntracellular Communication and SignalingIntracranial CNS DisordersIntracranial Central Nervous System DisordersInvestigationIsoformsLate Onset Alzheimer DiseaseLate onset ADMT-bound tauMacrophageMarrow NeutrophilMediatingMemory DeficitMemory impairmentMeta-AnalysisMiceMice MammalsMicrogliaModelingModern ManMurineMusNative ImmunityNatural ImmunityNerve DegenerationNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeuritic PlaquesNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeuron DegenerationNeutrophil InfiltrationNeutrophil RecruitmentNeutrophilic GranulocyteNeutrophilic InfiltrateNeutrophilic LeukocyteNon-Specific ImmunityNonspecific ImmunityOnset of illnessOutcomePeripheralPhenotypePlayPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPrimary Senile Degenerative DementiaProtein IsoformsRegulationResearchResolutionRisk-associated variantRoleSamplingSenile PlaquesSignal TransductionSignal Transduction SystemsSignalingSpatial DistributionTransgenic MiceTranslatingVariantVariationalzheimer riskamyloid beta plaqueamyloid-b plaqueapo E-4apo E4apo epsilon4apoE epsilon 4apoE-4apoE4apolipoprotein E epsilon 4apolipoprotein E-4apolipoprotein E4astrocytic gliaaβ plaquesbiological signal transductionbrain atrophybrain cellcerebral atrophycognitive dysfunctioncognitive functioncognitive losscored plaquecortical atrophydegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdiffuse plaquedisease onsetdisorder onsetgenetic risk factorgenome scalegenome-widegenomewidegitter cellhost responseiPSiPSCiPSCsimmune modulationimmune regulationimmune system responseimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimprovedin vivo Modelinduced pluripotent cellinduced pluripotent stem cellinducible pluripotent cellinducible pluripotent stem cellinherited factorinnate immune functioninnate immune pathwaysinsightlate onset alzheimermalememory dysfunctionmesogliamicroglial cellmicrogliocytemicrotubule bound taumicrotubule-bound taumouse modelmurine modelneural degenerationneural inflammationneurodegenerationneurodegenerativeneurodegenerative illnessneurodegenerative phenotypeneuroinflammationneuroinflammatoryneurological degenerationneuronal degenerationneuroprotectionneuroprotectiveneutrophilnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpatient living with Alzheimer's diseasepatient suffering from Alzheimer's diseasepatient with Alzheimer'spatient with Alzheimer's diseasepatients with ADperivascular glial cellprimary degenerative dementiarecruitresolutionsrisk allelerisk factor for developing Alzheimer'srisk factor in Alzheimer'srisk generisk genotyperisk locirisk locusrisk of developing Alzheimer'srisk variantsenile dementia of the Alzheimer typesexsocial roletautau Proteinstau factortooltrendτ Proteins
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

APOE4 is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD). The role of human APOE
variants in AD has been studied extensively in the regulation of microglia and astrocytes but not in neutrophils.

APOE is also expressed in neutrophils and controls their activation. Moreover, neutrophils have been shown to

play a negative role in AD mice via the induction of microgliosis. Thus, a key question is whether APOE variants

derived from neutrophils control immune responses driven by microglia and contribute to disease progression.

Our long-term goal is to define the role of APOE signaling in regulation neutrophil-microglia interactions in

neurodegeneration and determine which phenotypes and functions play a role in AD. We made the

following preliminary observations: 1) Induction of APOE expression in microglia in AD and tau mice is

associated with a phenotype switch from homeostatic (M0) to neurodegenerative microglia (MGnD); 2) APOE4

drives a neurodegenerative signature in neutrophils; 3) Recruited APOE4-neutrophils promote MGnD-microglia

in APP/PS1 and P301S mice. Based on these findings, we hypothesize that APOE4 inflammatory

neutrophils promote MGnD-microglia and accelerate neurodegeneration and cognitive decline in AD. We

will address our hypothesis in the following aims:

Aim 1: Define how APOE variants in neutrophils affects microglia. We propose to 1) Define the role of

APOE variants in neutrophils in the regulation of neutrophil-microglia crosstalk; and 2) Determine whether

replacement of APOE4 neutrophils with APOE2/3 neutrophils will restore microglial neuroprotective functions.

Aim 2: Define the impact of APOE variants in microglia on neutrophil recruitment to the diseased brain.

We will 1) Determine whether APOE variants modulate microglia to induce recruitment of neutrophils to the brain;

and 2) Investigate the spatial distribution of microglia and neutrophils in the brain of AD and tau mouse models.

Aim 3: Define the role of APOE variants in human neutrophils and their impact on human microglia in

AD. We propose to 1) Characterize human neutrophils isolated from APOE e2, e3 and e4 AD carriers and whether

they directly regulate the MGnD signature in iPSC-microglia; and 2) Investigate the neutrophil-microglia spatial

interactions in AD brain of human APOE e2, e3 and e4 AD carriers.

IN SUMMARY, targeting the APOE-neutrophil-microglia axis may provide a novel approach for therapeutic

modulation of innate immunity in AD and dementia.

Grant Number: 5R01AG075509-05
NIH Institute/Center: NIH

Principal Investigator: Oleg Butovsky

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →